Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B, Leonardi C, Papp KA, Mrowietz U, Ohtsuki M, Bissonnette R, Ferris LK, Paul C, Lebwohl M, Braun DK, Mallbris L, Wilhelm S, Xu W, Ljungberg A, Acharya N, Reich K. Strober B, et al. Among authors: leonardi c. J Am Acad Dermatol. 2017 Mar;76(3):432-440.e17. doi: 10.1016/j.jaad.2016.09.026. Epub 2016 Nov 23. J Am Acad Dermatol. 2017. PMID: 27889292 Free article.
Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials.
Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, Yeilding N, Guzzo C, Li S, Hsu MC, Strober B. Lebwohl M, et al. Among authors: leonardi c. J Am Acad Dermatol. 2012 May;66(5):731-41. doi: 10.1016/j.jaad.2011.06.011. Epub 2011 Sep 17. J Am Acad Dermatol. 2012. PMID: 21930328 Clinical Trial.
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Reich K, Leonardi C, Langley RG, Warren RB, Bachelez H, Romiti R, Ohtsuki M, Xu W, Acharya N, Solotkin K, Colombel JF, Hardin DS. Reich K, et al. Among authors: leonardi c. J Am Acad Dermatol. 2017 Mar;76(3):441-448.e2. doi: 10.1016/j.jaad.2016.10.027. Epub 2016 Dec 24. J Am Acad Dermatol. 2017. PMID: 28027825 Free article.
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Leonardi C, Reich K, Foley P, Torii H, Gerdes S, Guenther L, Gooderham M, Ferris LK, Griffiths CEM, ElMaraghy H, Crane H, Patel H, Burge R, Gallo G, Shrom D, Leung A, Lin CY, Papp K. Leonardi C, et al. Dermatol Ther (Heidelb). 2020 Jun;10(3):431-447. doi: 10.1007/s13555-020-00367-x. Epub 2020 Mar 21. Dermatol Ther (Heidelb). 2020. PMID: 32200512 Free PMC article.
The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Reich K, Puig L, Mallbris L, Zhang L, Osuntokun O, Leonardi C. Reich K, et al. Among authors: leonardi c. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1196-1207. doi: 10.1111/jdv.14252. Epub 2017 May 4. J Eur Acad Dermatol Venereol. 2017. PMID: 28370467 Clinical Trial.
Relapse, rebound, and psoriasis adverse events: an advisory group report.
Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D. Carey W, et al. Among authors: leonardi c. J Am Acad Dermatol. 2006 Apr;54(4 Suppl 1):S171-81. doi: 10.1016/j.jaad.2005.10.029. J Am Acad Dermatol. 2006. PMID: 16488339 Review.
435 results